Recurrence Score<sup>®</sup> Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial

Recurrence Score<sup>®</sup> Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial

Background: Patients with hormone receptor-positive (HR+), HER2-negative (HER2−) early breast cancer (eBC) with a high risk of relapse often undergo adjuvant chemotherapy. However, only a few patients will gain benefit from chemotherapy. Since classical tumor characteristics (grade, tumor size, lymp...

Full description

Bibliographic Details
Main Authors: Dominik Dannehl, Tobias Engler, Lea L. Volmer, Annette Staebler, Anna K. Fischer, Martin Weiss, Markus Hahn, Christina B. Walter, Eva-Maria Grischke, Falko Fend, Florin-Andrei Taran, Sara Y. Brucker, Andreas D. Hartkopf
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
oncotype DX
recurrence score
breast cancer
individualized therapy
Online Access:https://www.mdpi.com/2072-6694/14/21/5365

Similar Items

Similar Items